Shibata M, Watanabe M, Ueno Y, Sadamoto T, Sato G, Yasushi T, Yamagami T, Tuzimoto S, Enomoto M
Department of Internal Medicine, Kawasaki Central Hospital, Kanagawa, Japan.
J Gastroenterol. 1994 Feb;29(1):56-60. doi: 10.1007/BF01229074.
The DNA synthesis activities of hepatocytes in primary biliary cirrhosis (PBC) and other chronic liver diseases and control subjects were examined by staining proliferating cell nuclear antigen (PCNA) with anti-PCNA monoclonal antibody. The number of PCNA-positive cells (PCNA value) was significantly higher in PBC (375 +/- 281 parts per thousand; ppt) than in other chronic liver diseases, i.e., chronic hepatitis (95 +/- 83 ppt), liver cirrhosis (72 +/- 71 ppt), and alcoholic liver disease (73 +/- 56 ppt), and in control subjects (11 +/- 14 ppt). The PCNA value of PBC in stages I-III of Scheuer's classification was remarkably high, while in stage IV it was low. Even in identical, Scheuer's stages, the PCNA value of PBC was higher in patients who were not given ursodeoxycholic acid (UDCA) than in those who received UDCA. In identical patients, the PCNA value was lowered significantly after UDCA treatment. It was concluded that the DNA synthesis activity of PBC in stages I-III was accelerated and that UDCA can alleviate the abnormality in DNA synthesis activity.
采用抗增殖细胞核抗原（PCNA）单克隆抗体对原发性胆汁性肝硬化（PBC）、其他慢性肝病患者及对照者肝细胞的DNA合成活性进行检测。PBC患者的PCNA阳性细胞数（PCNA值）显著高于其他慢性肝病患者，即慢性肝炎（95±83‰）、肝硬化（72±71‰）、酒精性肝病（73±56‰）及对照者（11±14‰）。Scheuer分类法Ⅰ - Ⅲ期PBC患者的PCNA值非常高，而Ⅳ期则较低。即使在相同的Scheuer分期中，未接受熊去氧胆酸（UDCA）治疗的PBC患者的PCNA值也高于接受UDCA治疗的患者。对于同一批患者，UDCA治疗后PCNA值显著降低。研究得出结论，Ⅰ - Ⅲ期PBC患者的DNA合成活性增强，且UDCA可缓解DNA合成活性异常。
